FluorobexaroteneRXR agonist CAS# 1190848-23-7 |
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Etifoxine hydrochloride
Catalog No.:BCC1561
CAS No.:56776-32-0
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1190848-23-7 | SDF | Download SDF |
PubChem ID | 25195496 | Appearance | Powder |
Formula | C24H27FO2 | M.Wt | 366.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 25 mM in ethanol | ||
Chemical Name | 2-fluoro-4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid | ||
SMILES | CC1=CC2=C(C=C1C(=C)C3=CC(=C(C=C3)C(=O)O)F)C(CCC2(C)C)(C)C | ||
Standard InChIKey | LWKAWHRSPCHMPJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H27FO2/c1-14-11-19-20(24(5,6)10-9-23(19,3)4)13-18(14)15(2)16-7-8-17(22(26)27)21(25)12-16/h7-8,11-13H,2,9-10H2,1,3-6H3,(H,26,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | RXR agonist (Ki = 12 nM; EC50 = 43 nM at RXRα receptors). Displays similar RAR agonist activity to bexarotene; exhibits an apparent RXR binding affinity 75% greater than bexarotene. |
Fluorobexarotene Dilution Calculator
Fluorobexarotene Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7287 mL | 13.6437 mL | 27.2874 mL | 54.5747 mL | 68.2184 mL |
5 mM | 0.5457 mL | 2.7287 mL | 5.4575 mL | 10.9149 mL | 13.6437 mL |
10 mM | 0.2729 mL | 1.3644 mL | 2.7287 mL | 5.4575 mL | 6.8218 mL |
50 mM | 0.0546 mL | 0.2729 mL | 0.5457 mL | 1.0915 mL | 1.3644 mL |
100 mM | 0.0273 mL | 0.1364 mL | 0.2729 mL | 0.5457 mL | 0.6822 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fmoc-Asp-OH
Catalog No.:BCC3085
CAS No.:119062-05-4
- Euchrenone B1
Catalog No.:BCN3575
CAS No.:119061-09-5
- MRT67307
Catalog No.:BCC1779
CAS No.:1190378-57-4
- EB 47
Catalog No.:BCC2452
CAS No.:1190332-25-2
- PSI-7976
Catalog No.:BCC5138
CAS No.:1190308-01-0
- PSI-7977
Catalog No.:BCC1871
CAS No.:1190307-88-0
- Sarcandrone B
Catalog No.:BCN6074
CAS No.:1190225-48-9
- Sarcandrone A
Catalog No.:BCN6073
CAS No.:1190225-47-8
- M2 ion channel blocker
Catalog No.:BCC1726
CAS No.:1190215-03-2
- 4-[2-[(3-Ethyl-4-methyl-2-oxo-3-pyrrolin-1-yl)carboxamido]ethyl]benzenesulfonamide
Catalog No.:BCC8672
CAS No.:119018-29-0
- Abiesinol F
Catalog No.:BCN6418
CAS No.:1190070-91-7
- 2,2'-Biquinoline
Catalog No.:BCC8489
CAS No.:119-91-5
- Phellolactone
Catalog No.:BCN3467
CAS No.:1190897-23-4
- Linolenic acid ethyl ester
Catalog No.:BCN8333
CAS No.:1191-41-9
- 1-Acetoxy-5-deacetylbaccatin I
Catalog No.:BCN6357
CAS No.:119120-27-3
- IOWH-032
Catalog No.:BCC3922
CAS No.:1191252-49-9
- Ganomycin I
Catalog No.:BCN3504
CAS No.:1191255-15-8
- B-Raf inhibitor 1 dihydrochloride
Catalog No.:BCC4183
CAS No.:1191385-19-9
- 3-Oxosapriparaquinone
Catalog No.:BCN3153
CAS No.:119139-56-9
- Glychionide A
Catalog No.:BCN3250
CAS No.:119152-50-0
- Coronarin A
Catalog No.:BCN6075
CAS No.:119188-33-9
- Coronarin D
Catalog No.:BCN6076
CAS No.:119188-37-3
- Coronarin B
Catalog No.:BCN6077
CAS No.:119188-38-4
- 10-Hydroxyscandine
Catalog No.:BCN6078
CAS No.:119188-47-5
Divergent teratogenicity of agonists of retinoid X receptors in embryos of zebrafish (Danio rerio).[Pubmed:22526925]
Ecotoxicology. 2012 Jul;21(5):1465-75.
Zebrafish (Danio rerio) embryos were comparably exposed to seven known agonists of retinoid X receptors (RXRs) including two endogenous compounds (9-cis-retinoic acid and docosahexaenoic acid), four man-made selective ligands (LGD1069, SR11237, Fluorobexarotene and CD3254), and a biocide (triphenyltin). The dominant phenotypes of malformation were sharp mouths and small caudal fins in 1 mg/L SR11237-treated group after 5 days exposure. 9-cis-retinoic acid and LGD1069 induced multiple malformations including small eyes, bent notochords, reduced brain, enlarged proctodaems, absence of fins, short tails and edema after 5 days exposure. Fluorobexarotene and CD3254 induced similar phenotypes of malformations after 5 days exposure at low concentration (20 mug/L) to those after the 1st d exposure at high concentrations (50 and 100 mug/L). Triphenlytin induced multiple malformations including deformed eyes, bent notochords, bent tails, and edema in hearts after 5 days exposure at concentrations of 1-10 mug Sn/L. In contrast, no discernible malformations were observed in triphenlytin-treated groups after each separate day exposure. These agonists not only showed different ability of teratogenicity but also induced different phenotypes of malformation in zebrafish embryos. In addition, the sensitive stages of zebrafish embryos were different in response to these agonists. Therefore, our results suggest that the agonists of RXRs had divergent teratogenicity in zebrafish embryos.
Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).[Pubmed:19791803]
J Med Chem. 2009 Oct 8;52(19):5950-66.
This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated for RXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable K(i) and EC(50) values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties.